Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

0A4Y

Aim Immunotech (0A4Y)

Aim Immunotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0A4Y
DateHeureSourceTitreSymboleSociété
09/05/202414h50UK RegulatoryAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
06/05/202414h30UK RegulatoryAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®LSE:0A4YAim Immunotech Inc
29/04/202414h55UK RegulatoryAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerLSE:0A4YAim Immunotech Inc
10/04/202414h21UK RegulatoryAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerLSE:0A4YAim Immunotech Inc
02/04/202413h30UK RegulatoryAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateLSE:0A4YAim Immunotech Inc
26/03/202414h05UK RegulatoryAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
25/03/202414h05UK RegulatoryAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchLSE:0A4YAim Immunotech Inc
07/03/202414h45UK RegulatoryAIM ImmunoTech Announces Launch of CEO Corner PlatformLSE:0A4YAim Immunotech Inc
29/02/202414h45UK RegulatoryAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateLSE:0A4YAim Immunotech Inc
14/02/202414h55UK RegulatoryAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerLSE:0A4YAim Immunotech Inc
 Showing the most relevant articles for your search:LSE:0A4Y